– IW-6463 and olinciguat top line clinical study results remain on track for late summer and late Q3 2020, respectively –– Completed $24 million equity private placement to accelerate clinical development of IW-6463 for the CNS diseases MELAS (Mitochondrial Encephalomyopathy, Lactic Acidosis and Stroke-like episodes) and ADv (Alzheimer’s Disease with Vascular pathology) and of olinciguat for sickle cell disease –
– CNS focused webcast event held to highlight IW-6463 development plan and opportunity to address serious CNS diseasesCAMBRIDGE, Mass., Aug. 03, 2020 (GLOBE NEWSWIRE) — Cyclerion Therapeutics, Inc. (Nasdaq: CYCN), a clinical-stage biopharmaceutical company developing treatments for serious and orphan diseases, reported financial results for the second quarter ended June 30, 2020 and provided general corporate and pipeline updates.“We are looking forward to upcoming top line results from both our translational pharmacology study for IW-6463, the first brain-penetrant sGC stimulator to enter clinical development, and our STRONG olinciguat Phase 2 study for sickle cell disease. Both programs have the potential to provide a fundamentally new approach for patients with limited therapeutic options today”, said Peter Hecht, Ph.D., Chief Executive Officer of Cyclerion.Recent Program and Business Updates
Bay Street News